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Introduction: Therapeutic agents directed against the epidermal
growth factor receptor (EGFR) signaling pathway have been effec-
tive in the treatment of non-small cell lung cancer (NSCLC).
Cetuximab is a monoclonal antibody against the EGFR receptor
with antitumor activity in NSCLC. This study evaluated the efficacy
of cetuximab monotherapy after prior treatment with an oral EGFR
tyrosine kinase inhibitor (TKI).
Methods: Eligible patients had stage IIIB, IV, or recurrent NSCLC
with progression on the oral EGFR TKIs gefitinib or erlotinib.
Cetuximab was administered intravenously at 400 mg/m2 on day 1
and then 250 mg/m2 weekly until disease progression or unaccept-
able toxicity. The primary end point was response rate.
Results: Eighteen patients were enrolled. Patients were heavily
pretreated with chemotherapy and TKIs (average number of treat-
ments 4.2). The response rate was 0/18 (0%), and 28% of patients
had confirmed stable disease. Median progression-free survival was
1.8 months (95% confidence interval, 1.6–5.4 months), and median
overall survival was 7.5 months (95% confidence interval, 2.2–19
months). Three patients harbored activating EGFR mutations, and
one of them had stable disease for nearly 6 months on cetuximab.
Common toxicities were mild and included fatigue, skin rash, and
nausea/vomiting. Two patients developed interstitial lung disease,
life threatening in one case.
Conclusions: Cetuximab monotherapy administered after prior
EGFR TKI treatment in patients with advanced NSCLC does not
yield clinical responses.
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Aberrant activation of the epidermal growth factor re-ceptor (EGFR) tyrosine kinase occurs in a number of
epithelial malignancies, including non-small cell lung can-
cer (NSCLC).1 The signal network downstream of EGFR
plays an important role in multiple tumorigenic processes,
including cell cycle progression, angiogenesis, protection
from apoptosis, and metastasis.
Two classes of EGFR-directed targeted therapies have
demonstrated efficacy in patients with NSCLC. Cetuximab is
a monoclonal antibody that binds with high affinity to EGFR,
inducing tumor cell death by mechanisms including growth
arrest, apoptosis, and antibody-dependent cell-mediated cy-
totoxicity. Cetuximab has modest single-agent activity in
previously treated patients with advanced NSCLC, with a
response rate of 4.5%, stable disease (SD) rate of 30%, and
time to progression of 2.3 months.2 In the first-line treatment
of metastatic NSCLC, the addition of cetuximab to platinum-
containing doublets improves overall survival (OS) by ap-
proximately 1 month.3,4
The second class of EGFR therapeutics includes the
oral tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib,
which extend survival by a median of 2 months in unselected,
previously treated patients with NSCLC.5,6 Tumors contain-
ing gain-of-function mutations in the EGFR gene are partic-
ularly sensitive to TKI therapy, and first-line EGFR TKI
monotherapy is a viable alternative to chemotherapy in pa-
tients with advanced NSCLC harboring EGFR mutations.7
Preclinical observations had suggested that NSCLC
cell lines have differential responses to EGFR TKI therapy
and cetuximab,8 and transgenic mice with inducible EGFR-
mutant NSCLC responded to prolonged cetuximab treat-
ment.9 This study was designed to determine whether cetux-
imab monotherapy has activity in patients previously treated
with an EGFR TKI and whether patients with EGFR muta-
tions have a higher likelihood of response. Response was
chosen for the primary end point to simplify a two-stage
design, although progression-free survival (PFS) and OS
were prespecified secondary end points.
METHODS
We recruited patients to this multicenter, single-arm,
phase II clinical trial with Eastern Cooperative Oncology
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Group performance status 0 to 2 and stage IIIB, IV, or
recurrent NSCLC who were previously treated with erlotinib
or gefitinib but failed treatment because of progression or
drug intolerance. Patients with asymptomatic, stable brain
metastases were eligible.
Patients received intravenous cetuximab, 400 mg/m2,
followed by weekly infusions of 250 mg/m2. Four weekly
treatments constituted one cycle, and CT scans were per-
formed every two cycles to document response. A designa-
tion of partial response or SD required confirmation as
defined by RECIST. All radiographs were centrally reviewed
at Massachusetts General Hospital.
All patients were required to have an available tissue
sample for EGFR mutation testing, which was performed
centrally at a Clinical Laboratory Improvement Amend-
ments-certified laboratory and involved extraction of
genomic material from paraffin-embedded tissue, followed
by polymerase chain reaction amplification and direct se-
quencing of exons 19 and 21 as previously described.10
The trial used a Simon two-stage design, which en-
rolled 18 patients in the first stage of accrual. The trial was to
proceed to enroll 28 evaluable patients if 1 or more response
was observed in the first group. This design provided a 57%
chance of early termination if the true response rate was
3%. PFS (survival without disease progression or death)
and OS were calculated using the Kaplan-Meier method.
The clinical trial protocol was approved and moni-
tored by the local institutional review board at all sites, and
all patients provided written informed consent. Data were
compiled and analyzed centrally at Massachusetts General
Hospital.
RESULTS
Eighteen eligible patients were enrolled in the first
stage of the trial between October 2006 and March 2009.
Patients were primarily women with heavily pretreated (av-
erage number of prior treatments  4.2) adenocarcinoma
(Table 1). Of three patients with tumors harboring EGFR
mutations, all previously responded to TKI therapy (range,
6–21 months). The remaining patients had SD or progressive
disease on prior TKI therapy, with a median treatment dura-
tion of 7 months.
After treatment with cetuximab, none of the patients
met the criteria for a clinical response, but five patients
(28%) had confirmed SD (median, 5.4 months). The re-
mainder of the patients either had progressive disease or
unconfirmed SD.
At the time of analysis, the median potential fol-
low-up was 20 months and minimum follow-up was 12
months. No patients remain on treatment, but five patients
were still alive. The median PFS is 1.8 months (95%
confidence interval, 1.6 –5.4 months) (Figure 1A), and the
median OS is 7.5 months (95% confidence interval, 2.2–19
months) (Figure 1B).
Skin-related treatment related toxicity was the most
common adverse event (Table 2). Serious events included
interstitial lung disease, angina-like chest pain, headache, and
shortness of breath/wheezing. One patient had a first-dose
infusion reaction that precluded further treatment.
Three patients with EGFR mutations were treated with
cetuximab. One of three had confirmed SD. The time to
progression for these individuals was 1.1, 1.8, and 5.5 months
and OS was 1.1, 4.5, and 14 months, compared with a median
PFS of 1.8 months and OS of 6.6 months for all patients on
the trial.
KRAS mutation status was also available for four pa-
tients. Of these, two were positive for KRAS mutations and
two were wild-type. Three progressed at the 2-month fol-
low-up scan, but one wild-type patient remained on cetux-
imab for 6 months.
TABLE 1. Characteristics of Patients (n  18) Treated with
Cetuximab
Patients, n (%)
Age (yr)
Median 66
Range 49–87
Sex
Male 4 (22)
Female 14 (78)
Smoking history
Never 5 (28)
10 pack-years 13 (72)
Brain metastases at enrollment
No 14 (78)
Yes 4 (22)
Histology
Adenocarcinoma 15 (83)
NOS 3 (17)
Activating EGFR mutation 3 (17)
Ethnicity
Asian 1 (6)
Other 17 (94)
ECOG PS
0 4 (22)
1 10 (56)
2 4 (22)
Number of prior systemic therapies
1–2 1 (6)
3–4 8 (44)
5–6 9 (50)
Previous TKI
Erlotinib 17a (94)
Gefitinib 3a (17)
Response to prior TKI (n  16)
Complete response 1b (6)
Partial response 2b (11)
Stable disease 8 (44)
Progressive disease 5 (28)
a Two patients received both erlotinib and gefitinib as previous therapy.
b These patients had EGFR mutations.
NOS, not otherwise specified; EGFR, epidermal growth factor receptor; TKI,
tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status.
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DISCUSSION
Cetuximab monotherapy demonstrated no responses, a
SD rate of 28%, and PFS of 1.8 months in a population of
patients previously treated with EGFR TKI therapy. Of note,
the patient population in this study was heavily pretreated,
possibly biasing toward a lower likelihood of response to any
additional therapy. Despite this, our results are fairly similar
to those previously reported in a phase II study of single-
agent cetuximab in less-refractory patients.2
When this trial was initiated, it was hoped that patients
with tumors harboring EGFR mutations may be more sensitive
to cetuximab therapy as preclinical models suggested that cetux-
imab may be active against EGFRmutant cell lines. In addition,
a published report described a patient with an exon 19 deletion
mutation who responded to cetuximab before gefitinib or erlo-
tinib therapy.11 Among our three patients with EGFRmutations,
we saw no responses. One patient with an exon 19 deletion and
prior complete response to erlotinib lasting 10 months achieved
SD on cetuximab for 6 months, which was one of the longest
periods of benefit from treatment in our study. Furthermore,
repeat biopsy of this patient’s tumor after TKI therapy had
demonstrated an acquired T790M resistance mutation. In pre-
clinical work, mice harboring xenograft tumors containing an
exon 19 deletion and T790M had dramatic tumor responses
when treated with the combination of cetuximab and the irre-
versible EGFR TKI, BIBW2992.12 Although concurrent EGFR
blockade with cetuximab and a TKI may be challenging because
of overlapping toxicities, clinical trials using such combinations
and modeled after the preclinical models are underway in pa-
tients with acquired TKI resistance.13,14
Although cetuximab seems to be a modestly effective
drug in combination with chemotherapy for first-line treat-
ment of NSCLC, the search for predictive biomarkers has
been disappointing. Biomarkers that have been tested include
increased EGFR gene copy number, EGFR protein expres-
sion by immunohistochemistry, and KRAS mutations, but
none have been validated in NSCLC.3,4,15 Hopefully, future
investigations will be able to identify an effective biomarker
to help select patients most likely to respond to cetuximab
and other anti-EGFR antibodies.
A B
FIGURE 1. Kaplan-Meier curves for progression-free survival (A) and overall survival (B) among all treated patients.
TABLE 2. Treatment-Related Adverse Events, 10%
Frequency or Clinically Significant
Event
Grade, n (%)
1 2 3 4 Total
Rash 6 (33) 2 (11) 0 0 8 (44)
Dry skin 5 (28) 0 0 0 5 (28)
Fatigue 2 (11) 2 (11) 0 0 4 (22)
Erythema 4 (22) 0 0 0 4 (22)
Cough 4 (22) 0 0 0 4 (22)
Pruritus 2 (11) 1 (6) 0 0 3 (17)
Nausea 3 (17) 0 0 0 3 (17)
Vomiting 3 (17) 0 0 0 3 (17)
Interstitial lung
disease
0 0 1 (6) 1 (6) 2 (11)
Chest pain 1 (6) 0 1a (6) 0 2 (11)
Headache 1 (6) 0 1 (6) 0 2 (11)
Diarrhea 2 0 0 0 2 (11)
Wheezing 1 (6) 0 1 (6) 0 2 (11)
Hypersensitivity
reaction
0 1b (6) 0 0 1 (6)
a Cetuximab was discontinued because of grade 3 angina possibly related to study
treatment occurring 5 d after treatment.
b Cetuximab was discontinued because of hypersensitivity on initial infusion.
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